How should the attractiveness of a gene or cell therapy market be assessed?
Assessment should combine target patient population size, disease severity, unmet medical need, clinical-stage maturity, efficacy and safety data, manufacturing capacity, treatment cost, reimbursement conditions and competitive intensity. Sectorious reports help compare opportunities across CAR-T, in vivo gene therapies, gene editing and allogeneic cell therapies to prioritize indications with the strongest clinical, industrial and commercial rationale.